Archemix Corp. and Merck Serono, a division of Merck KGaA, have formed a multi-year strategic alliance to discover, develop and commercialize aptamer therapeutics with a focus on cancer treatments. The alliance combines Archemix’ SELEX technology to discover and generate aptamer candidates with Merck’s oncology drug development and commercialization capabilities. In addition, Archemix and Takeda have signed a multi-year, three-target agreement that also focuses on the discovery, deve...